Introduction {#sec1}
============

Respiratory viral infections are of global public health concern because they are the most common cause of symptomatic disease leading to a heavy economic burden due to an increased number of sick days ([@ref22]; [@ref81]). In addition, respiratory diseases are one of the most common causes of mortality in developing countries ([@ref49]). Among the two leading causes of respiratory virus infection are influenza (A and B) viruses and the respiratory syncytial virus (RSV) ([@ref9]; [@ref65]; [@ref167]). Most cases are observed in infants and children although the elderly and the immunocompromised are also at high risk of getting infected and develop severe disease ([@ref76]).

While influenza viruses and RSV circulate seasonally between beginning of fall and early spring, the increased numbers of avian influenza (H7N9) in China including highly pathogenic (HP) strains of the virus, the continued outbreaks of the HP avian influenza (HPAI) H5N1 viruses, novel variants of seasonal influenza viruses (H3N2var), and the emergence of the Middle East respiratory syndrome coronavirus (MERS-CoV) highlight the serious and important need for developing novel, more effective antiviral therapies ([@ref173]; [@ref68]). This review article focuses on therapies currently under development for treatment of influenza, RSV, and MERS-CoV infections. We will briefly review drugs that have been approved by the United States Federal Drug Administration (FDA) and then drugs that are in clinical trials ([Figure 1](#fig1){ref-type="fig"}). When available, the clinical trial identifier is included.

![Mechanisms of action of different antivirals. A diagram of the virus life cycle of **(A)** influenza virus, **(B)** respiratory syncytial virus, and **(C)** Middle East respiratory syndrome coronavirus, indicating where each therapeutic exerts its antiviral activity. Drugs approved by the FDA are shown in bold.](fmicb-10-01327-g001){#fig1}

Influenza Virus {#sec2}
===============

Influenza virus is a negative sense, segmented RNA virus that presents a substantial burden to human health. Despite the availability of successful vaccines and antivirals, infection with seasonal influenza viruses is still the cause of 3--5 million cases of severe illnesses and up to 300--650 thousand deaths worldwide ([@ref159]). In the US alone, it is estimated that seasonal influenza affects up to 9 million people a year resulting in 12,000--56,000 deaths annually ([@ref28]). The economic burden is estimated to be in the tens of billions of dollars ([@ref117]). In addition, pandemic influenza outbreaks emerge at unpredictable intervals causing increased morbidity, mortality, and a negative economic impact ([@ref47]).

Currently Federal Drug Administration-Approved Anti-influenza Antivirals {#sec3}
------------------------------------------------------------------------

Briefly, these drugs can be divided in three groups: the M2 ion channel blockers, the neuraminidase inhibitors (NAIs), and the virus polymerase inhibitors. Amantadine and rimantadine are adamantane derivatives that inhibit viral replication by blocking the proton conductivity of the M2 ion channel preventing delivery of the virus ribonucleoprotein in the cytoplasm ([@ref126]; [@ref69]). These compounds are specific for influenza A viruses since the M2 protein of influenza B viruses is structurally different ([@ref153]; [@ref116]). In recent past seasons, surveillance studies reported high levels of resistance (\>99%) to adamantanes among circulating influenza A(H3N2) and influenza A(H1N1)pdm09 viruses, and the centers for disease control and prevention (CDC) does not recommend these compounds for antiviral treatment or chemoprophylaxis of currently circulating influenza A viruses ([@ref26]). Development of NAI started in the early 1970s with derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid ([@ref111]), although it was not until 1999 that the first NAI was approved for use in humans ([@ref32]). The NAI binds to the neuraminidase of the virus and prevents its cleavage, thus inhibiting the release of new virus particles ([@ref69]). NAIs currently approved by the FDA include: oseltamivir, zanamivir, and peramivir. Oseltamivir acid is a pro-drug indicated for oral administration. Once in the gastrointestinal tract, the pro-dug is rapidly cleaved to the active metabolite, oseltamivir carboxylate ([@ref81]). Due to poor oral bioavailability, zanamivir is approved for inhalation delivery with intravenous administration only available by compassionate use ([@ref69]; [@ref129]). Peramivir also has poor oral bioavailability; therefore, it has been approved for intravenous administration only. Because the drug reaches high concentrations in plasma and respiratory tissues, it has been approved as a single-dose infusion. One of the inherit problems of these drugs is that, in order to be effective, treatment should start within 48 h post-exposure. Antiviral resistance to oseltamivir, zanamivir, and peramivir is very low in currently circulating influenza virus strains, although this can change because several clusters of oseltamivir resistance have been detected in Japan, Australia, and China ([@ref138]; [@ref4]; [@ref84]). Also known as S-033188, baloxavir marboxil (Xofluza®) is a pro-drug that is hydrolyzed *in vivo* to S-033447, the active form that selectively inhibits cap-dependent endonuclease, preventing the initiation of mRNA synthesis of the influenza virus ([@ref139]). This is a potent small molecule that shows activity against several influenza A viruses, including oseltamivir-resistant viruses as well as B viruses ([@ref106]). Preclinical studies demonstrated that treated mice infected with influenza virus were protected from clinical signs and mortality even in a delay of treatment approach (treatment started 4 days post-infection). Furthermore, a subtherapeutic dose of baloxavir in combination with oseltamivir also protected mice from infection and mortality ([@ref53]). In addition, studies in mice infected with avian influenza viruses such as H5N1 or H7N9 also demonstrated protection after oral administration with baloxavir ([@ref151]). A clinical study (NCT02954354) aimed to compare the efficacy of baloxavir with a placebo or oseltamivir in healthy patients infected with influenza demonstrated that the drug was well tolerated and was associated with a significant reduction in viral load compared to the oseltamivir group. Time of alleviation of symptoms was similar to oseltamivir. The currently undergoing clinical program for this drug includes phase 3 clinical trials to determine safety, pharmacokinetics, and efficacy in healthy pediatric participants aged less than 1 year (NCT03653364) or in pediatric patients with influenza-like symptoms (NCT03629184) and a study to assess efficacy and safety of baloxavir in combination with standard-of-care neuraminidase inhibitor in hospitalized participants with severe influenza (NCT03684044). These studies are currently recruiting and expected to be concluded in spring 2020. In Japan, baloxavir has been approved for the treatment of adult and infant patients infected with influenza; while in the US, the drug has just been approved by the FDA for the treatment of acute, uncomplicated influenza in people aged 12 years and older ([@ref50]). The emergence of resistant variants to polymerase inhibitors has been observed and it is conferred by an I38T mutation in the PA polymerase ([@ref74]). In the same study, a novel mutation conferring resistance (E23K) was also observed. Both mutations have been encountered during clinical trials for baloxavir ([@ref63]).

Promising Drug Candidates in the Pipeline {#sec4}
-----------------------------------------

Given the inherit limitations of these currently approved compounds and the potential risk for the arising of antiviral resistance, there is still an urgent need for developing new anti-influenza drugs. These novel drugs should have some (ideally all) of the following characteristics: effective when delivered late in infection, low propensity for developing antiviral resistance, broad activity (influenza A and B), improved effectiveness compared to the standard of care, and can be easily administered in uncomplicated as well as complicated cases of influenza ([@ref84]; [@ref129]). Next, we will summarize the most advanced (phase 2 and 3 clinical trials), promising drug candidates.

Viral Targeting Candidates {#sec5}
==========================

Antibodies {#sec6}
----------

New and more efficient technologies for the production of monoclonal antibodies (mAbs) have stimulated the development of novel mAbs-based therapies for influenza and other infectious diseases ([@ref72]). A number of broadly neutralizing mAbs targeting the conserved stalk region of the influenza virus hemagglutinin (HA) molecule are currently under development. In addition, a non-neutralizing mAb targeting the virus matrix protein is also in clinical trials.

### CR6261 and CR8020 {#sec7}

CR6261 is directed against a highly conserved helical region in the membrane-proximal stalk of hemagglutinin. *In vitro* studies on this class of mAbs demonstrated neutralization activity across a broad spectrum of influenza A subtypes. CR6261 is protective in mice against lethal doses of H1N1 and H5N1 viruses ([@ref85]). A challenge study successfully demonstrated both therapeutic and prophylactic efficacy in the ferret model against a lethal dose of an H5N1 virus ([@ref51]). A clinical trial phase 2 (NCT02371668) aimed to determine if the CR6261 reduces flu disease in people treated with this drug versus a placebo has concluded but results are still not available. CR8020 targets an immunosubdominant, relatively conserved membrane-proximal stalk region of hemagglutinin. The mAb is active against group 2 influenza viruses and has been shown to have neutralization activity against H3, H7, and H10 subtypes both *in vitro* and *in vivo* ([@ref45]). A phase 2a trial to evaluate the protective efficacy and safety of CR8020 in an influenza challenge model was completed in 2014 (NCT01938352). Unfortunately, a recent study showed that CR8020 targets a region of the HA stalk that is prone to escape, therefore escape mutants are likely to arise ([@ref142]).

### CT-P27 {#sec8}

This product contains two distinct but complementary mAbs that have shown broad efficacy *in vitro* and *in vivo* against different group 1 and group 2 influenza viruses. A phase 2a clinical trial (NCT02071914) was conducted to evaluate the efficacy and safety of CT-P27 in an influenza challenge model. The study concluded in July 2014, however no results were reported. Currently recruiting, a phase 2b clinical trial (NCT03511066) is aimed to evaluate the efficacy and safety of the mAbs combo in comparison to placebo in subjects with acute uncomplicated influenza A infection.

### MEDI8852 {#sec9}

This is a potent, broadly neutralizing investigational human IgG1 mAb targeting a highly conserved stalk region of the HA protein. MEDI8852 has been reported to effectively neutralize all known influenza A HA subtypes ([@ref77]). Preclinical studies in animal models have shown efficacy in protecting against H5N1 influenza virus lethal challenges when used alone or in combination with oseltamivir ([@ref114]). A phase 2a study (NCT02603952) to evaluate the safety of MEDI8852 in adults with acute, uncomplicated influenza was recently concluded and results demonstrated an acceptable safety profile in this group of patients. In 2016, MEDI8852 received Fast Track designation by the FDA that allows the drug an expedite development and review ([@ref5]).

### MHAA4549A {#sec10}

This is a human monoclonal IgG1 antibody containing a VH 3-30 59 heavy chain paired with a Vκ1-15 light chain ([@ref96]). MHAA4549A targets a highly conserved epitope on the stalk region of HA and is capable of neutralizing all tested seasonal human influenza A strains ([@ref105]). Two mechanisms of action have been described for this mAb, one by binding the HA to avid virus infectivity and two by antibody-dependent cell-mediated cytotoxicity to increase killing of infected cells ([@ref96]). Preclinical studies demonstrated efficacy in the mouse model against a diverse group of influenza viruses including group 1 and group 2 strains even when administered 72 h post-infection. In addition, synergism was observed when administered with oseltamivir at 48 h post-infection. Finally, studies in ferrets demonstrated protection against an H5N1 HPAI virus challenge ([@ref105]). A few clinical trials have been conducted to evaluate safety, pharmacokinetics, and efficacy of MHAA4549A alone or in combination with oseltamivir ([@ref86]; [@ref96]; [@ref36]). Results established that the mAb is well tolerated with a half-life similar to other human antibodies (\~23 days) but with a nonlinear nasal pharmacokinetics ([@ref96]; [@ref36]). Furthermore, treatment significantly reduced viral loads ([@ref96]). The most recent clinical trial (NCT02293863) aimed to investigate the safety and clinical activity of a single intravenous (IV) dose of MHAA4549A in adult participants hospitalized with severe influenza A in combination with oseltamivir was recently concluded and results indicated no advantage on any of the primary clinical outcomes evaluated when compared with the standard of care. Furthermore, no significant differences were observed in any of the virologic outcomes evaluated including viral shedding or peak of virus load.

Virus Polymerase Inhibitors {#sec11}
---------------------------

### Pimodivir {#sec12}

This is a novel, non-nucleoside polymerase inhibitor that targets the PB2 subunit of influenza A viruses. Targeting the PB2 avoids docking of the 7-methyl GTP cap structure, thus preventing viral RNA synthesis ([@ref33]; [@ref23]). The early activity of pimovidir in the cell cycle has shown to improve cell viability compared to oseltamivir ([@ref24]). Furthermore, it is active against a diverse group of influenza A viruses including the H1N1pdm, H5N1, and H7N9 ([@ref24]). Preclinical studies in mice demonstrated protection against a lethal challenge even when given 4 days post-infection with H1N1pdm or H5N1 viruses ([@ref24]). Further studies also showed protection against a lethal challenge using an H3N2 virus ([@ref133]). Studies using pimodivir and oseltamivir suggest a potential benefit for a combination therapy ([@ref147]). A phase 2b clinical study (NCT02342249) treatment with pimodivir significantly decreased viral load over 7 days versus placebo, in adult patients with acute, uncomplicated seasonal influenza A. Recently, pimodivir has received FDA Fast Track designation due to its potential to address an unmet medical need in those who develop influenza A infection complications. A phase 3 clinical trial (NCT03381196) aimed to evaluate the efficacy and safety of pimodivir in combination with oseltamivir in adults at risk of developing complications is currently recruiting patients and it is expected to be concluded in October 2019.

### Favipiravir {#sec13}

Formerly known as T-705, this substituted pyrazinecarboxamide derivative is an inhibitor of the influenza virus polymerase. As a purine nucleoside analog, favipiravir directly inhibits the activity of the RNA-dependent RNA polymerase ([@ref55]) and it has broad-spectrum activity against all influenza subtypes including those resistant to neuraminidase and M2 inhibitors ([@ref54]). Preclinical studies demonstrated the broad antiviral spectrum of this compound against different human and avian influenza A and B viruses including avian influenza viruses H5N1 and H7N9 ([@ref130]; [@ref155]) where it has shown protection and reduction of virus titers in the infected mice. Furthermore, mice treated with favipiravir had a better outcome after an H7N9 infection compared to mice treated with neuraminidase inhibitors ([@ref155]). Combination therapy studies found that this drug works synergistically with neuraminidase inhibitors to improve lung virus titers, body weight loss, and survival in mice infected with a pandemic H1N1 influenza virus ([@ref141]) or with an avian influenza virus H5N1 ([@ref134]). Favipiravir is approved in Japan, but its use is restricted to patients infected with an influenza virus resistant to NAI or in the event of a pandemic (Toyama Chemical Co. Ltd). These conditions have been put in place due to concerns of teratogenicity, which have been identified in animal experiments. A couple of phase 3 clinical trials aimed to determine the efficacy and safety of favipiravir for the treatment of uncomplicated influenza infection in adults have been completed but the results have not been published yet. A new phase 2a clinical trial study to determine the pharmacokinetics of favipiravir in patients with severe influenza is reported as active but not currently recruiting with estimated study completion date of March 2019 (NCT03394209). This is a very promising broad-spectrum anti-influenza antiviral that also has a broad antiviral activity against several other RNA viruses ([@ref35]). A couple of caveats may limit the use of this antiviral to compassionate use or in the case of emerging or re-emerging viruses for which a treatment is not available. Favipiravir has the potential for teratogenicity and embryotoxicity and is the reason why it has conditional approval in Japan ([@ref54]). A study of samples obtained for a clinical trial tested the emergence of mutations in viruses obtained from paired patients before and 1 or 2 days after the initiation of treatment showed the emergence of amino acid substitutions in the RNA polymerase subunits. Although these mutations did not significantly reduce the susceptibility to favipiravir ([@ref137])*, in vitro* escalation studies showed that influenza viruses can adapt to low concentration of the compound which highlights the potential for some influenza virus strains to possibly develop resistance ([@ref109]).

Host-Targeting Candidates {#sec14}
=========================

Fludase {#sec15}
-------

Also known as DAS-181, this is a recombinant sialidase composed of the catalytic domain of a bacterial sialidase (*Actinomyces* *viscosus*) and the epithelium-anchoring domain of the human protein amphiregulin ([@ref91]). In the human respiratory tract, cell surface sialic acids are the primary receptors for binding and entry of influenza viruses. Fludase works by removing sialic receptors from the airway epithelium, therefore preventing viral entry into cells of the respiratory epithelium ([@ref150]). Preclinical *in vitro* studies show that fludase is a broad-spectrum anti-influenza antiviral with potent antiviral activity against human and avian influenza viruses with no cellular toxicity ([@ref149], [@ref148]). *In vivo* studies showed that mice can be rescued from influenza infection after treatment with fludase, including after infection with highly pathogenic H5N1 and H7N9 viruses ([@ref17]; [@ref92], [@ref93]). In a randomized, double-blind, placebo-controlled phase 2 study conducted to determine the effective dose in healthy adult participants with laboratory-confirmed influenza (NCT01037205), it was observed that treatment with fludase significantly reduces viral load and viral shedding after multiple doses. In addition, no significant adverse effects were observed in the patients that received the treatment ([@ref103]). In a phase 1 clinical trial (NCT01651494), it was observed that in longer treatments (more than 7 days), patients developed antibodies against the compound leading to a reduced efficacy ([@ref168]).

Nitazoxanide (Alina^®^) {#sec16}
-----------------------

Nitazoxanide (NTZ) was originally developed and licensed as an antiprotozoal drug for the treatment of enteritis caused by *Cryptosporidium* and *Giardia* infections. Nitazoxanide is a thiazolide compound that is rapidly deacetylated in the blood to the active metabolic form tizoxanide ([@ref120]). In addition to its antiparasitic activity, this compound has shown activity against a broad range of viruses including influenza viruses ([@ref16]; [@ref145]; [@ref135]). The mechanism of action against influenza virus is achieved by impairing the trafficking of the viral hemagglutinin (HA) from the endoplasmic reticulum to the Golgi apparatus and by blocking HA terminal glycosylation leading to block maturation of the HA ([@ref121]). Preclinical studies demonstrated an antiviral activity against different strains of influenza A, and B viruses *in vitro* including avian influenza viruses ([@ref132]). There are not published studies of the antiviral efficacy of NTZ in animal models, although extensive pharmacological testing has been performed in animals ([@ref84]). Nitazoxanide is an example of a repurposed drug with a lot of studies in humans, which is facilitating the advancement of this drug as a treatment for influenza virus infection ([@ref120]). A phase 2b/3 clinical trial (NCT01227421) aimed to determine the safety and efficacy of NTZ in the treatment of acute uncomplicated influenza established that treatment with 300 mg twice a day for 5 days was well tolerated and it was associated with a reduction of symptoms and infectious viral load ([@ref60]). A phase 3 study (NCT03336619) to evaluate the efficacy and safety of 300-mg nitazoxanide tablets ([@ref135]) in the treatment of uncomplicated influenza was concluded in March 2019 but results have not been posted.

Respiratory Syncytial Virus {#sec17}
===========================

Respiratory syncytial virus is the most commonly identified cause of acute lower respiratory tract infection in infants, children, immunocompromised adults, and the elderly ([@ref172]; [@ref58]). Since the first isolation of the virus from chimpanzees in 1956 ([@ref102]), extensive research has been conducted in epidemiology, diagnosis, and animal models for the infection, but there is no vaccine and only two approved antivirals available against the virus ([@ref166]).

RSV is a non-segmented virus with negative sense single-stranded RNA genome encoding 11 proteins. Out of those, two surface transmembrane proteins, G and F, have been shown to play a key role in RSV binding and fusion, respectively. The virus is classified into two subtypes: A and B, with about 50% genetic diversity in the G gene and 10% differences in the F gene ([@ref144]; [@ref166]). Due to less antigenic variability of the F protein compared with the G protein, this protein is the main target of research for developing antivirals as well as anti-RSV vaccines ([@ref140]).

Currently Federal Drug Administration-Approved Anti-Respiratory Syncytial Virus Antivirals {#sec18}
------------------------------------------------------------------------------------------

There are only two RSV antiviral drugs approved by the FDA for the treatment or prevention of serious respiratory tract infections caused by RSV: aerosolized ribavirin for treatment and palivizumab (Synagis^®^) for prophylaxis.

The guanosine analog ribavirin is a broad-spectrum antiviral agent with activity against RSV and other RNA viruses such as hepatitis C and Zika viruses ([@ref10]; [@ref82]; [@ref171]). The beneficial effect of this drug in inhibiting RSV replication was demonstrated in several studies. Ribavirin showed antiviral activity against RSV and reduced RSV lung titers in infected cotton rats ([@ref19]). Similarly, significant clinical benefits have been observed in children treated with aerosolized ribavirin early in infection ([@ref40]). However, the clinical application of ribavirin is limited because of its nonspecific anti-RSV activity, risks for potential toxicity, and relatively high cost ([@ref136]).

Palivizumab is a humanized monoclonal antibody found to have strong RSV-neutralizing capability against a range of RSV strains. The palivizumab 24-aa epitope structure on the RSV F protein is well characterized ([@ref125]). The drug has been shown to be effective in preventing RSV-related hospitalizations in children ([@ref52]). Although the efficacy of this antiviral against RSV infection is proven, due to the considerable cost of palivizumab, the usage is limited to the high-risk populations ([@ref127]) including infants and young children ([@ref27]).

Promising New Antiviral Candidates in the Pipeline {#sec19}
==================================================

In recent years, in addition to the FDA-approved RSV antivirals, a number of alternative strategies against RSV including new recombinant antibodies, nanobodies, small molecules such as fusion inhibitors, nucleoprotein inhibitors, nucleoside analogs, and non-nucleoside inhibitors are being developed.

Antibodies {#sec20}
----------

Intravenous polyclonal immunoglobulin (IVIG) is a preparation of human serum that contains high titers of neutralizing antibodies against the virus. Usage of IVIG in severe RSV infections in high-risk children significantly reduced the rate of hospitalizations due to related respiratory infections ([@ref143]). Currently, new recombinant mAbs against RSV are in different stages of development.

### RI-001 and RI-002 {#sec21}

These are aqueous intravenous polyclonal human immunoglobulin G (IgG) from pools of source plasma of screened healthy adult donors with high levels of RSV-neutralizing antibodies. The results of a phase 1 and a 2 study on RI-001 and RI-002, respectively, demonstrated that the preparation met acceptable pharmacokinetic and safety criteria, and achieved a fold-change increase in titer of anti-RSV neutralizing antibodies in patients ([@ref154]).

### REGN2222 {#sec22}

REGN2222 is a fully human IgG1 mAb produced in VelocImmune mice that binds specifically to the F protein of RSV. Preclinical studies in cotton rats demonstrated that REGN2222 is effective at reducing RSV viral replication in the lungs ([@ref59]). Although the results of two clinical trials in phase 1 in healthy adults showed that the antibody was well tolerated and it had a half-life longer than typical IgG1 mAbs with low immunogenicity ([@ref131]), the results of a recent phase 3 trial in preterm infants revealed that this mAb did not meet its primary endpoint of preventing RSV.

### MEDI8897 {#sec23}

MEDI8897 is a recombinant human IgG1κ mAb with an engineered Fc region to have a longer serum half-life and designed for prevention of lower respiratory tract illness (LRTI) caused by RSV. The antibody binds to the prefusion conformation of the F protein of RSV. The results of placebo-controlled studies in healthy adults and healthy preterm infants showed an increase in the mean half-life of MEDI8897. Moreover, the safety profile of MEDI8897 was similar to placebo ([@ref57]; [@ref43]). To evaluate the efficacy of this mAb in preventing infection, further clinical studies are still needed in the target population of infants entering their first RSV season.

### ALX-0171 {#sec24}

ALX-0171, the first nanobody developed for treatment of RSV infection, is a trivalent nanobody (42 kDa) that binds the antigenic site II of the RSV F protein and neutralizes both subtypes of RSV. *In vitro* neutralization efficiency of ALX-0171 is greater than palivizumab ([@ref38]). Preclinical studies in cotton rats and neonatal lambs have indicated that ALX-0171 is highly effective in reducing both nasal and lung RSV titers ([@ref62]; [@ref37]). The results of phase 1 and 2 clinical studies demonstrated that inhaled ALX-0171 inhibited RSV replication and reduced viral load compared to placebo. ALX-0171 is currently in clinical trials (NCT03418571) to treat infants hospitalized with RSV infection ([@ref152]).

### mAb 131-2G {#sec25}

131-2G is a murine mAb that binds to the central conserved region of the RSV G protein and interferes with the attachment process by blocking the G protein from binding to CX3CR1 ([@ref73]). RSV-challenged mice studies showed that early treatment with this mAb reduced both pulmonary inflammation and lung virus titers ([@ref64]). Clinical studies are needed to evaluate the safety and efficacy of this antiviral in humans.

### Motavizumab {#sec26}

Motavizumab is a recombinant humanized mAb that binds to a 24-residue, linear, conformational epitope FFL on the RSV F glycoprotein ([@ref170]). Preclinical studies in cotton rats demonstrated that the mAb decreased RSV titers more than 50 times in lungs in comparison to palivizumab ([@ref163]). Phase 1 and 2 clinical trials showed that motavizumab is well tolerated in healthy adults and premature infants as well as in high-risk children with chronic lung disease of prematurity ([@ref1]; [@ref107]). The results of a recent phase 3 clinical trial to prevent serious RSV disease in healthy term infants indicated that motavizumab reduced the proportion of infants admitted to the hospital with RSV ([@ref107]).

Fusion Inhibitors (Small Molecules) {#sec27}
-----------------------------------

Numerous studies have evaluated the virus-host interactions to determine the viral and host factors that contribute to replication of viruses. For RSV replication, both the co-receptors that become localized on the epithelium in response to virus-mediated signals and the RSV F protein contribute to this process ([@ref66]). Most antiviral small molecules that bind to the F protein can block membrane fusion and viral penetration, and subsequently inhibit RSV replication ([@ref14]).

### GS-5806 {#sec28}

GS-5806 is an orally bioavailable RSV fusion inhibitor that has been shown to prevent RSV entry by blocking the virus-cell fusion process ([@ref124]). In a preclinical study conducted in cotton rats, an efficient bioavailability and penetration of the drug in lung tissue were observed. The results of a clinical study in healthy volunteers experimentally infected with RSV indicated that oral administration of GS-5806 resulted in reduction of viral load and disease severity ([@ref89]). More clinical trials have been completed in different populations including in RSV-infected hospitalized patients, lung transplant recipients, and in hematopoietic stem cell transplantation recipients, but the results are not available yet. Recently published results for phase 2b trials in hospitalized adults with RSV did not show significant reduction in viral load or improvement of clinical outcomes to the disease ([@ref61]). To clarify the efficacy of this drug, further studies are required in infants and children.

### MDT-637 {#sec29}

MDT-637 (VP-14637) is a fusion inhibitor that has been shown to inhibit RSV entry to the cells. Both *in vitro* reports and preclinical studies in cotton rats demonstrated the anti-RSV activity of MDT-637. This compound is effective against both subtypes of RSV ([@ref81]). The reformulated form of MDT-637, VP-14637, can be administered by powder inhaler with a quick delivery to the respiratory tract ([@ref165]). The results of phase 1 clinical trials indicated a safety and desirable pharmacokinetic profile of the drug in healthy adults (NCT01475305) ([@ref81]).

### JNJ-53718678 {#sec30}

JNJ-678 is a potent RSV-specific fusion inhibitor that has been shown to act as an effective anti-RSV *in vitro* and in animal models ([@ref123]; [@ref2]). Clinical studies in healthy adults assessed its antiviral efficacy as well as safety. It was shown that JNJ-53718678 reduced RSV viral load, respiratory infections' severity caused by RSV, and duration of the disease ([@ref71]; [@ref67]). Further studies are needed in infants and children to prove the antiviral activity of this anti-RSV candidate.

### AK-0529 {#sec31}

AK-0529 is a novel compound being developed to inhibit RSV replication by blocking viral entry into the target cells. A placebo-controlled phase 1 clinical trial showed that oral administration of this antiviral is well tolerated among healthy volunteers and meets the standard safety profile ([@ref146]). A phase 2 clinical trial in hospitalized infants infected with RSV is currently underway (NCT02654171).

### TMC353121 {#sec32}

TMC353121, a small substituted benzimidazole RSV fusion inhibitor, is an improved derivative of JNJ-2408068 \[a compound with antiviral activity against both RSV A and B, but with long tissue retention times in animal models which created concerns and stopped its further development ([@ref164]; [@ref20])\].TMC353121, in contrast to JNJ-2408068, lacks the long tissue retention but maintains its high antiviral activity *in vitro* ([@ref21]). Using TMC353121 in preclinical studies in cotton rats ([@ref122]) and African green monkeys ([@ref70]) revealed a reduction in viral loads in a dose-dependent manner and in lung inflammation. Based on these data, TMC353121 could be a drug candidate for treatment of RSV infection; however, safety studies and more clinical evaluations are still needed.

Nucleoprotein Inhibitors {#sec33}
------------------------

One promising area of development revolves around inhibitors of RSV that target the virus nucleoprotein. RSV nucleoprotein is involved in virus assembly and it is crucial for the virus replication. Less genetic variation of this protein among RSV A and B subtypes makes it an amenable molecular target for development of anti-RSV compound ([@ref34]).

### RSV-604 {#sec34}

RSV604 is a small molecule with submicromolar RSV activity that was discovered through chemical optimization of an RSV high-throughput screen hit ([@ref31]). It is effective against both RSV A and B replication at a post-entry step. The antiviral mechanism of this compound is related to its binding to the RSV N protein and therefore inhibition of both RNA synthesis and the infectivity of released virus ([@ref29]). A phase 2a clinical trial in stem cell transplant patients with RSV infection showed that following treatment with RSV604, plasma exposure reached the 90% effective concentration (EC~90~). In addition, patients had a reduction in viral titers and RSV infection symptoms ([@ref94]).

### ALN-RSV01 {#sec35}

ALN-RSV01 is a small interfering RNA (siRNA) with 19 nucleotides targeting a highly conserved region of the RSV nucleoprotein gene. This siRNA has shown to be effective in both prophylaxis and treatment models. Results of a preclinical study in mice indicate that treatment with ALN-RSV01 achieved up to 3-logs reduction in RSV lung titers in comparison to control groups ([@ref87]). Intranasal administration of ALN-RSV01 in healthy volunteers inoculated with RSV showed a significant reduction of RSV infection in active drug recipients when compared to the placebo recipients group ([@ref41]). In a phase 2 clinical trial conducted in lung transplant recipients with RSV infection, a good safety profile and positive benefits of this siRNA were observed in reducing the risk of bronchiolitis obliterans syndrome ([@ref56]). Further evaluations of this antiviral in naturally RSV-infected children and infants should be established.

Nucleoside Analog and Non-nucleoside Inhibitors {#sec36}
-----------------------------------------------

### ALS-008176 {#sec37}

ALS-008176 (4 chloromethyl-2-deoxy-3,5-di-O-isobutyryl-2-fluorocytidine) is a nucleoside RSV polymerase inhibitor with a high level of oral bioavailability. A preclinical study in African green monkeys infected with RSV and treated orally demonstrated an efficient antiviral activity ([@ref39]). A clinical trial in healthy adults experimentally infected with RSV revealed shorter RSV RNA clearance time in the ALS-008176 treated group compared with placebo recipients, and the reduction in RSV viral load ranged from 73 to 88% in nasal washes of ALS-008176 treated individuals ([@ref42]).

Middle East Respiratory Syndrome {#sec38}
================================

MERS is an emerging zoonotic disease caused by a virus called MERS coronavirus (MERS-CoV). This virus is an enveloped, single-stranded, positive sense RNA virus with a large genome (approximately 30 kb in length) belonging to the C lineage of *Betacoronavirus* ([@ref46]; [@ref156]).

The disease was first reported in 2012 in the Middle East and since then multiple introductions to the human population have occurred from the dromedary, the only known animal reservoir of MERS-CoV ([@ref156]; [@ref75]; [@ref110]). The majority of the 2,374 cases reported up to date ([@ref161]) have occurred in Saudi Arabia (1983 cases). The disease has been reported in 27 countries from different continents with most of them associated with recent travel to the Arabic peninsula ([@ref112]). Person-to-person transmission has been well documented especially in health care workers and family members and may lead to large outbreaks with a significant impact on public health as observed in the Middle East and Korea ([@ref80]; [@ref99]). People from any age can be infected with the virus, although the majority of cases have been observed in adults ([@ref25]). Clinical features range from asymptomatic or mild to severe disease and death ([@ref174]; [@ref118]). Symptoms may include respiratory illness that can lead to acute respiratory distress syndrome ([@ref13]; [@ref98]) and digestive symptoms including nausea, vomiting, and diarrhea ([@ref25]) with some patients developing renal failure ([@ref18]; [@ref75]). The case fatality rate worldwide is 34.6%, while in Saudi Arabia it is 37.5% ([@ref161]).

To date, there are no licensed vaccines or therapeutics for prevention or treatment of MERS-CoV infection and therapy is focused on supportive care to relive symptoms and in more severe cases to also support function of vital organs ([@ref100]; [@ref104]). Since no specific treatment is available, supportive therapy and the use of broad-spectrum antivirals are currently the options for treatment ([@ref119]). A broad range of therapeutics have been used in the clinic to treat MERS-CoV-infected patients, and their use is based on knowledge obtained during the severe acute respiratory syndrome (SARS) outbreak in 2003 and the recent influenza pandemic in 2009 ([@ref99]). Furthermore, comprehensive clinical studies are lacking and only field data are available ([@ref44]).

Therapies that have been used for treatment of patients infected with MERS-CoV include convalescent sera, corticosteroids, and/or antiviral therapeutics including interferons, ribavirin, and protease inhibitors (or combination of members from these groups)([@ref8]; [@ref115]; [@ref173]; [@ref7]; [@ref104]). There is a long list of potential therapeutics in preclinical phase that have shown promising results *in vitro* and in animal models. Comprehensive reviews of the current therapeutics under development have been published elsewhere ([@ref173]; [@ref44]; [@ref119]).

Convalescent Plasma {#sec39}
-------------------

The use of plasma obtained from recovering patients (convalescent plasma) has shown beneficial effects in outbreaks of SARS and influenza virus infections ([@ref6]). Studies in these infections indicated that the use of CP can reduce viral loads and mortality ([@ref90]; [@ref162]). Due to the lack of clinical data demonstrating efficacy in MERS-CoV infection, the use of CP is considered an investigational treatment by the WHO ([@ref158]). Only two cases have been reported to use intravenous immunoglobulin as part of an integral treatment intervention; therefore, a beneficial effect was not readily quantifiable ([@ref78]; [@ref12]). In preclinical studies, passive transfer of sera from MERS-CoV immune camels to infected mice reduced weight loss and lung histopathology ([@ref169]). A protocol to determine the safety and effectiveness of CP therapy for patients infected with MERS-CoV was recently published ([@ref12]). In this study, the authors concluded that due to the variation in the levels of MERS-CoV-specific immunoglobulins in recovered patients, a large screening will be necessary to obtain sufficient plasma donors. A clinical study was registered based on these findings, but since then, it has been withdrawn (NCT02190799). The use of CP remains as a potential therapeutic intervention but the lack of evidence to prove its safety and efficacy in treating infected patients limits its potential impact ([@ref104]).

Polyclonal Human Antibody Produced in Transchromosomic Cattle {#sec40}
-------------------------------------------------------------

Transchromosomic cattle have been developed to produce fully human polyclonal IgG antibodies following immunization ([@ref95]). Using this technology, polyclonal sera containing antibodies against the spike protein of MERS-CoV were produced (SAB-301) and demonstrated to be effective in neutralizing the virus *in vitro* and reducing lung virus titers in infected mice ([@ref88]). A phase 1 randomized clinical trial aimed to evaluate the safety and tolerability of SAB-301 was conducted (NCT02788188). Results have been published and showed that the polyclonal human antibody is safe and well tolerated in patients at what could be considered therapeutic doses ([@ref15]).

Monoclonal Antibodies Produced in Humanized Mice {#sec41}
------------------------------------------------

Using their VelocImmune mice, Regeneron produced fully human mAbs binding the spike protein of MERS-CoV. Two lead mAb candidates (REGN 3051 and REGN 3048) were further characterized *in vitro* and *in vivo* ([@ref113]). *In vitro*, both mAbs potently neutralized the MERS-CoV while *in vivo* studies in a mouse model of infection demonstrated that treatment of infected mice caused a reduction in lung virus titers and histopathology ([@ref113]). A phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single ascending doses of a combination of both mAbs administered IV in healthy adult volunteers is currently underway (NCT03301090).

Broadly Acting Antivirals {#sec42}
-------------------------

One of the main strategies implemented in the clinics for the treatment of MERS-CoV is the use of broadly acting antivirals although supportive therapy continues to be the primary approach for treatment ([@ref100]). Antivirals such as interferon and ribavirin that show strong inhibition of MERS-CoV *in vitro* have been used in the clinics with different degrees of success. Ribavirin is a synthetic guanosine nucleoside that interferes with the synthesis of viral mRNA. The best effect has been observed using a combination therapy of interferon (IFN) and ribavirin ([@ref101]). Different type I interferons including IFN-α2b and IFN-β1b have been used in the management of patients with confirmed MERS-CoV infection ([@ref97]). In a study using macaques, animals were treated with IFN-α2b and ribavirin staring at 8 h after infection with MERS-CoV ([@ref48]). The infected animals were euthanized at 72 h post-infection which is the peak of disease in this model. The group that received the combination treatment did not developed overt clinical signs of infection, had reduced levels of pro-inflammatory cytokines, reduction in lung virus titers, and reduction in overall lung pathology compared to the group of macaques that did not receive treatment. Most of the data on the efficacy of this combination therapy are from retrospectives studies ([@ref99]; [@ref97]). In a study comparing infected patients that received this combination therapy in addition to support therapy, it was observed that these patients had a significantly better survival at day 14 post-laboratory confirmation of the infection (70%) compared to the patients that only received the supportive therapy (29%) ([@ref108]). In a case study report of a health worker infected with MERS-CoV, the use of IFN-α2b plus ribavirin was associated with his recovery as well as with a beneficial prophylactic effect in his spouse who only developed a mild respiratory illness ([@ref79]). IFN-β has also been used in combination therapies for the treatment of MERS-CoV infection ([@ref128]; [@ref11]). In a retrospective study that analyzed a small cohort of patients with laboratory-confirmed infection, it was observed that treatment with the combination of IFN-β1a and ribavirin did not significantly improve survival ([@ref128]). In a different retrospective study, analysis of the data demonstrated that administration of IFN-β improved survival in treated patients. However, after a multivariate analysis, the positive effect was not significant ([@ref3]). Results vary between different retrospective studies and this is in part due to the presence of comorbidities and most importantly the time for treatment initiation ([@ref7]), since it has been observed that the window of opportunity is very narrow and only effective when started within the first 48 h of confirmed diagnosis ([@ref101]; [@ref8]; [@ref157]). A case study of a MERS-CoV-infected patient who received ribavirin in combination with lopinavir/ritonavir (Kaletra®), a human immunodeficiency virus antiviral, and IFN-α2a, reported that this regimen was effective to treat the patient ([@ref83]). The patient, a 64-year-old male with different comorbidities, started treatment on day 4 post admission and achieved viral clearance just 6 days after initiation of treatment and finally was discharged from the hospital on day 13 after admission ([@ref83]). In a recent study, a combination of ribavirin and lopinavir/ritonavir was used as a post-exposure prophylaxis in health care workers who had been exposed to MERS-CoV-infected patients and demonstrated a reduction of 40% in the risk of infection ([@ref112]). A preclinical study in common marmosets infected with MERS-CoV showed that treatment with a combination of lopinavir/ritonavir and IFN-β1b improved the clinical and pathological outcomes of the infected animals ([@ref30]). A phase 2/3 clinical trial NCT02845843 to determine the feasibility, efficacy, and safety of a combination therapy with lopinavir/ritonavir and IFN-β1b for the treatment of MERS-CoV-infected patients was initiated in 2016. The clinical trial was expected to be concluded in July of 2018; however, no results or activity have been reported.

Conclusions {#sec43}
===========

This review summarizes the current antivirals available for the treatment of influenza and RSV along with potential new therapies for these respiratory virus infections ([Table 1](#tab1){ref-type="table"}). It also addresses the current therapies employing broad-spectrum antivirals for the treatment of MERS-CoV-infected patients ([Table 1](#tab1){ref-type="table"}). Greater advances have been achieved in the field of influenza antivirals. Currently, three groups of drugs are approved for the treatment of influenza, including the newly approved viral polymerase inhibitor baloxavir marboxil and only one approved for RSV, the polyclonal palivizumab. Although effective, these drugs have limitations such as a reduced window of opportunity, potential to produce drug-resistant viruses, and high cost (Palivizumab). This highlights the need for more and better antiviral drugs to treat these respiratory infections. MERS-CoV recently emerged as a zoonotic respiratory infection and, therefore, no effective antivirals are approved for treatment. The initial approach has been to follow examples of antiviral therapies used during the recent SARS outbreak; however, as described in this review, the approach using broad-spectrum antivirals has not been very successful.

###### 

Novel therapeutics currently under development (clinical trials), for the treatment of influenza virus, respiratory syncytial virus (RSV), and Middle East respiratory syndrome coronavirus (MERS-CoV).

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Therapeutic compound      Infectious agent   Mechanism(s) of action                                             Clinical trial phase   NCT\#
  ------------------------- ------------------ ------------------------------------------------------------------ ---------------------- --------------
  CR6261                    Influenza          Inhibits the binding of the virus to cell membrane receptor        2a                     NCT02371668

  CT-P27                    Influenza          Inhibits the binding of the virus to cell membrane receptor        2b                     NCT03511066\
                                                                                                                                         NCT02071914

  MEDI8852                  Influenza          Inhibits the binding of the virus to cell membrane receptor        2a                     NCT03903718\
                                                                                                                                         NCT03028909\
                                                                                                                                         NCT02603952

  MHAA4549A                 Influenza          Inhibits the binding of the virus to cell membrane receptor        2                      NCT01980966\
                                                                                                                                         NCT02623322\
                                                                                                                                         NCT02293863

  Pimodivir                 Influenza          Prevents viral RNA synthesis                                       3                      NCT03381196

  Favipiravir               Influenza          Inhibits the activity of the RNA-dependent RNA polymerase          3                      NCT02026349\
                                                                                                                                         NCT02008344

  Fludase                   Influenza          Prevents viral entry into cells of the respiratory epithelium      2                      NCT01037205

  Nitazoxanide              Influenza          Impairs the trafficking of the viral hemagglutinin                 3                      NCT03336619

  RI-001                    RSV                Inhibits the binding of the virus to cell membrane receptor        2                      NCT00632463

  REGN2222                  RSV                Viral fusion protein inhibitor                                     3                      NCT02325791

  MEDI8897                  RSV                Viral fusion protein inhibitor                                     2                      NCT02878330

  ALX-0171                  RSV                Viral fusion protein inhibitor                                     2                      NCT03418571

  131-2G                    RSV                Interferes with the attachment process by blocking the G protein   Pre-clinical           NA

  Motavizumab               RSV                Viral fusion protein inhibitor                                     3                      NCT00121108\
                                                                                                                                         NCT00628303\
                                                                                                                                         NCT00129766

  GS-5806                   RSV                Blocks the virus-cell fusion process                               2                      NCT01756482\
                                                                                                                                         NCT02534350\
                                                                                                                                         NCT02254408\
                                                                                                                                         NCT02254421\
                                                                                                                                         NCT02135614

  MDT-637                   RSV                Inhibits virus entry to the target cells                           1                      NCT01489306\
                                                                                                                                         NCT01355016\
                                                                                                                                         NCT01556607

  JNJ-53718678              RSV                Viral fusion protein inhibitor                                     2                      NCT03656510\
                                                                                                                                         NCT03379675\
                                                                                                                                         NCT02387606

  AK-0529                   RSV                Inhibits virus entry to the target cells                           2                      NCT03699202\
                                                                                                                                         NCT02654171

  TMC353121                 RSV                Viral fusion protein inhibitor                                     Pre-clinical           NA

  RSV-60444                 RSV                Inhibits RNA synthesis and the infectivity of released viruses     2a                     NCT00232635

  ALN-RSV01                 RSV                Inhibits RNA replication                                           2                      NCT00658086\
                                                                                                                                         NCT01065935\
                                                                                                                                         NCT00496821

  ALS-008176                RSV                Inhibits RSV polymerase                                            2                      NCT02094365\
                                                                                                                                         NCT02673476

  Convalescent plasma       MERS-CoV           Inhibits virus entry to the target cells                           2                      NCT02190799

  SAB-301                   MERS-CoV           Inhibits virus entry to the target cells                           1                      NCT02788188

  REGN 3051 and REGN 3048   MERS-CoV           Inhibits virus entry to the target cells                           1                      NCT03301090

  Ribavirin                 MERS-CoV           Interferes with the synthesis of viral mRNA                        1                      NCT02627378
  -----------------------------------------------------------------------------------------------------------------------------------------------------

Great advances have been made in the last few years and several antivirals are currently under development and many have reached early stages in clinical trials. This is a very exciting and evolving field that will continue producing more effective antivirals that are highly needed for the treatment of respiratory viral infections of global public health concern.
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